Back to results
US 6,713,268 B2Granted
Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
AssigneeAllergan, Inc.
InventorsDavid F. Woodward, Licheng Shi, Achim H-P Krauss, Clayton S. Spada, Sheila Mac Neil, Linda C. Smith-Thomas
Life of this patent
Estimating the term…
Abstract
Methods to identify agents having ocular hypotensive activity which have reduced or absent ability to stimulate iridial hyperpigmentation are disclosed. The methods reside in part in detecting the ability of a test compound to interact with the FP receptor.
Claims6
A method to identify a compound having ocular hypotensive activity with reduced or absent ability to stimulate iridial hyperpigmentation comprising:
- contacting a test compound having ocular hypotensive activity and a population of melanin-producing cells co-cultured with fibroblasts or cells of a fibroblast-derived lineage displaying the prostaglandin FP receptor, and evaluating the ability of the compound to stimulate melanin formation;
- wherein a compound which fails to stimulate melanin formation to an equivalent or greater extent than an amount of latanoprost having the same hypotensive activity is identified as a compound having reduced or absent ability to stimulate iridial hyperpigmentation.
Dependencies are inferred from the claim text.